Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
IntoCell
Welcome,
Profile
Billing
Logout
Products
Diseases
Products
Trials
News
||||||||||
The combination therapy with B7-H3 antibody drug conjugates for effective radiation treatment
(Section 52) - Mar 5, 2024 - Abstract #AACR2024AACR_6222;
Abstract is embargoed at this time.
|
|||||||||
Journal:
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
(Pubmed Central) - Aug 19, 2023
Our preclinical data indicate that ITC-6102RO is a promising therapeutic agent for B7-H3-targeted therapy. Moreover, we anticipate that OHPAS linkers will serve as a valuable platform for developing novel ADCs targeting a wide range of targets.